FDA ends GLP-1 compounding for semaglutide, tirzepatide

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.

Featuring: Sara Heath, executive editor, Xtelligent Healthcare

Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare

In today’s episode, we’ll cover…

• The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions
• Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications
• Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections

and more!
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
To watch the video clips of our podcast, subscribe to our YouTube channel,
@EyeOnTech.

References:

• Anticipating the healthcare reach of GLP-1 receptor agonists
• Are compounded GLP-1 drugs safe?
• FDA winds down GLP-1 compounding policies